News · 26 weeks40-20%
2026-04-192026-10-11
Mix1390d
- SEC Filings6(46%)
- Other4(31%)
- Earnings2(15%)
- Leadership1(8%)
Latest news
25 items- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026Preclinical data showed that balanced PPARα, PPARδ and PPARγ activation by lanifibranor affects complementary pathways across multiple hepatic cell populations involved in fibrosis in MASH pathogenesisPreclinical data and Phase 2b clinical results showed lanifibranor improved liver sinusoidal endothelial cell alterations and was associated with changes in intrahepatic vascular abnormalities across multiple stages of diseaseAnalysis of plasma cell-free DNA (cfDNA) identified coordinated epigenetic changes across the PPAR family in patients with MASLD, supporting the biological rationale for targeting multiple PPAR isoforms Daix (France), New York City (New York, United States), October 6, 20
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate UpdateCash and cash equivalents at €166.1 million and €67.8 million in short-term deposits1 as of June 30, 2026Cash runway guidance remains unchanged from July 30, 20262Topline results of the Phase 3 NATiV3 clinical trial are expected in the fourth quarter of 2026Key highlights from the first half of 2026 and recent Company updatesManagement to host webcast today at 8:00 AM ET to discuss first-half 2026 financial results Daix (France), New York (New York, United States), September 28, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohep
- PRInventiva to Present Multiple Abstracts at Paris MASH 2026Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetesPreclinical data further characterize lanifibranor’s balanced pan-PPAR pharmacology and support a differentiated fluid and cardiac profile relative to TZDs and dual PPARα/γ agonists Daix (France), New York (New York, United States), September 8, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announces the presentation of five abstracts at th
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASHLast patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohortTopline results of NATiV3 expected in Q4 2026September investor conference participation and timing of H1 2026 financial results update Daix (France), New York (New York, United States), September 2nd, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral small molecule therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the last patient has completed their final 72-week visit in the NATiV3 Phase 3 clinical tr
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva Appoints Chris Benecchi as Chief Operating OfficerDaix (France), New York City (New York, United States), August 31, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the appointment of Chris Benecchi as Chief Operating Officer. A proven biopharmaceutical leader with extensive experience in building organizations, preparing medicines for launch and integrating cross-functional operations, Mr. Benecchi will lead Inventiva's operational readiness as the Company approaches its pivotal NATiV3 Phase 3 topline study results of lanifibranor, in MASH, exp
- SECAmendment: SEC Form 6-K/A filed by Inventiva S.A.6-K/A - Inventiva S.A. (0001756594) (Filer)
- PRCorrection: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026 Daix (France), New York City (New York, United States), July 30, 2026 – Update to Press Release Dated July 29, 2026. The Company wishes to correct an error in the press release issued on July 29, 2026. On page 2, the potential proceeds for the Tranche C of the Debt Financing Transaction was mistakenly stated as €20 million. The correct figure is €55 million. All other information in the press release remains unchanged. As a result, the corrected version shall read as follows: Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical c
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva Announces Preliminary Financial Results for the First Half of 2026¹Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026 Daix (France), New York City (New York, United States), July 29, 2026 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported certain preliminary financial results for the first half of 2026, including its cash, cash equivalents and revenues. Preliminary Financial Results As at June 30, 2026, the Company’s cash and cash equivalents amounted to €166.1 million and €67.8 million in shor
- ANALYSTCantor Fitzgerald initiated coverage on InventivaCantor Fitzgerald initiated coverage of Inventiva with a rating of Overweight
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB WarrantsDaix (France), New York City (New York, United States), July 9, 2026 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), is pleased to announce the completion of the final step of the transactions previously announced on June 2, 2026 (the "Combined Transaction") through the issuance of approximately 15.7 million new warrants (bons de souscription d’actions) (the "New EIB Warrants") to the European Investment Bank (the "EIB") and the surrender and cancellation of all remaining warrants originally issued
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRResults of the Votes of the Combined Shareholders’ General Meeting of June 30, 2026Daix (France), New York City (New York, United States), July 2, 2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the results of the votes of its Combined Shareholders’ Meeting. The Combined Shareholders' Meeting was held on Tuesday June 30, 2026, at 2 p.m. at Hôtel Villa M, 24-30 Bd Pasteur, 75015 Paris (France), under the chairmanship of Mr. Andrew Obenshain, Chief Executive Officer of Inventiva. Mr. Andrew Obenshain proceeded to the usual formalities of the opening of the meeting, in particu
- PRClaret Capital Partners participates in €130m financing for InventivaClaret Capital Partners participates in €130m financing for Inventiva Inventiva is a clinical biopharmaceutical company developing an oral treatment for chronic liver disease, MASHClaret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financingLatest in a series of late stage, European biotech investments by Claret Capital as part of its expansion in life sciences London, 16 June, 2026, Claret Capital Partners (‘Claret'), Europe's largest independent growth debt fund manager has made an investment through its funds, of €43m in Inventiva (Euronext Paris and NASDAQ:IVA), a clinical-stage biopharmaceutical company developing an oral therapy for the tr
- PRClaret Capital Partners participates in €130m financing for Inventiva to support Phase 3 developmentClaret Capital Partners participates in €130m financing for Inventiva Inventiva is a clinical biopharmaceutical company developing an oral treatment for chronic liver disease, MASHClaret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financingLatest in a series of late stage, European biotech investments by Claret Capital as part of its expansion in life sciences London, 16 June, 2026, Claret Capital Partners (‘Claret'), Europe's largest independent growth debt fund manager has made an investment through its funds, of €43m in Inventiva (Euronext Paris and NASDAQ:IVA), a clinical-stage biopharmaceutical company developing an oral therapy for the tr
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRInventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt FinancingRepaid in full the existing EIB Loans1 in an amount of approximately €62 million and completed repurchase of all 2,266,023 existing EIB Tranche A Warrants and 700,000 of existing EIB Tranche B Warrants2 (corresponding to approximately 22.7 million Underlying Shares) for a repurchase price of €50 million Issued the Tranche A Convertible Bonds (€35 million) and the Tranche B Amortized Bonds (€40 million), for an initial aggregate drawdown of €75 million under the Debt Financing Transaction3 with funds and accounts managed by BlackRock and Claret Capital Partners Daix (France), New York City (New York, United States), June 12, 2026 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or th
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- SECSEC Form 6-K filed by Inventiva S.A.6-K - Inventiva S.A. (0001756594) (Filer)
- PRCombined General Meeting of June 30, 2026 - Availability of the Preparatory DocumentsDaix (France), New York City (New York, United States), June 9,2026 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the availability of the preparatory documents for the Combined General Meeting of June 30, 2026. Shareholders are invited to participate in the Combined General Meeting that will be held on June 30, 2026 at 2 p.m. at Hôtel Villa M, 24 – 30 Boulevard Pasteur, 75015 Paris (France). The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on
IVA FAQ
7 questionsWhat does Inventiva S.A. do?
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie...Where does IVA stock trade?
Inventiva S.A. (IVA) is listed on NASDAQ.What sector and industry is IVA in?
Inventiva S.A. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Inventiva S.A. go public?
Inventiva S.A. (IVA) completed its IPO in 2020.What are analysts saying about IVA?
Inventiva S.A. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-07-17. Recent price targets range from $1200.00 to $2600.00.What companies are similar to IVA?
Notable peers in the same industry include GNFT (GENFIT S.A.), GLTO (Galecto Inc.), CMMB (Chemomab Therapeutics Ltd.). Compare IVA side-by-side with any of them on Quantisnow.How can I track IVA on Quantisnow?
Quantisnow aggregates Inventiva S.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IVA to receive live email and push alerts on every new disclosure.